Maegim한국어

에이비엘바이오

298380KOSDAQSector: Pharma & Biotech
₩69,300 1.28%Market cap ₩3.88TAs of Jul 21, 2026 close · updated once daily
D
Grade D37.5 ptsTop 75% of 2,523 stocks
Financial strength
34.1
Growth momentum
54.5
Price attractiveness
29.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

34.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
79.3%
Below median · Top 66.5% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
142.6%
Below median · Top 59.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-50.9%
Below median · Top 68.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-24.4%
Below median · Top 70.1% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

54.5
How much did revenue grow in a year?
Revenue growth (YoY)
137.6%
Above median · Top 7.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
5.6%
Above median · Top 46.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
32.0%
Above median · Top 28.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-4548.2%
Below median · Top 99.7% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

29.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Above median · Top 48.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
25.06x
Below median · Top 93.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15